JPH05269353A - Production of high-ganglioside composition - Google Patents
Production of high-ganglioside compositionInfo
- Publication number
- JPH05269353A JPH05269353A JP4100708A JP10070892A JPH05269353A JP H05269353 A JPH05269353 A JP H05269353A JP 4100708 A JP4100708 A JP 4100708A JP 10070892 A JP10070892 A JP 10070892A JP H05269353 A JPH05269353 A JP H05269353A
- Authority
- JP
- Japan
- Prior art keywords
- ganglioside
- membrane
- milk
- pore size
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Dairy Products (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、ガングリオシド含有量
の高い組成物の製造方法に関する。得られた組成物は、
ガングリオシド含有量が高いので母乳代替品、機能性食
品あるいは医薬品の原料として利用することができる。FIELD OF THE INVENTION The present invention relates to a method for producing a composition having a high ganglioside content. The composition obtained is
Because of its high ganglioside content, it can be used as a raw material for breast milk substitutes, functional foods or pharmaceuticals.
【０００２】[0002]
【従来技術とその背景】ガングリオシドは、シアル酸を
含有する酸性スフィンゴ糖脂質の総称である。近年、ガ
ングリオシドの生物学的研究が盛んになり、神経細胞の
増殖促進、ウィルス感染防御、細菌毒素中和能、インタ
ーフェロンやホルモンの受容体等の生理活性が確認され
ている。また特に、ガングリオシドは細胞表面に局在す
る特異な活性物質として、動物の脳などに多く存在する
ことも知られている。ガングリオシドは乳中にも存在
し、永井ら（脂質化学研究27,182-185(1985)）が牛乳で
の形態を明らかにし、また高見沢 (酪農科学食品の研究
37,259-273(1988)）が人乳、牛乳、ヤギ乳での組成につ
いて報告している。2. Description of the Related Art Ganglioside is a general term for acidic glycosphingolipids containing sialic acid. In recent years, biological research on gangliosides has been actively conducted, and physiological activities such as promotion of nerve cell growth, protection against virus infection, neutralizing ability of bacterial toxin, and receptors for interferon and hormone have been confirmed. It is also known that, in particular, ganglioside is abundant in the brain of animals as a specific active substance localized on the cell surface. Ganglioside is also present in milk, Nagai et al. (Lipid chemistry research 27, 182-185 (1985)) is to clarify the form of milk, also Takamizawa (study of dairy science and food
37, 259-273 (1988)) is human milk, cow's milk, are reported on the composition of goat milk.
【０００３】一方、調製方法に関しては、細菌毒素中和
剤として知られている (特開昭60-72819号公報）。ここ
で使われるガングリオシドは、バターミルクを透析、硫
安分剤、ゲル濾過、等電点沈澱などの方法で精製し、さ
らに超音波処理して脂肪球皮膜断片として用いられてい
る。しかし、この方法で得られる断片は、たんぱく質含
有量が高く、必ずしもガングリオシドを高濃度に含んで
いるとはいえない。また、柳平ら (特開昭63-269992 号
公報) が牛乳ガングリオシドの濃縮調製法を開示してい
る。その方法はたんぱく質分解酵素を作用させ、得られ
たたんぱく質分解液を限外濾過膜処理を行なうものであ
る。しかし、この方法は、操作が複雑であり、夾雑物多
く、生成したペプチドにより苦味が生成し、呈味性が悪
いなどの問題点があった。このため、ガングリオシド含
有量の高い組成物を母乳代替品、機能性食品等の食品及
び医薬品原料として利用するために単純な工程で、しか
も夾雑物の生成を低く抑えて生産できる工業的規模での
製造方法の開発が強く望まれていた。On the other hand, regarding the preparation method, it is known as a bacterial toxin neutralizing agent (JP-A-60-72819). The ganglioside used here is used as a fat globule membrane fragment obtained by purifying buttermilk by a method such as dialysis, ammonium sulfate dispersant, gel filtration, and isoelectric focusing, followed by ultrasonic treatment. However, the fragment obtained by this method has a high protein content, and it cannot be said that it contains a high concentration of ganglioside. In addition, Yanagidaira (JP-A-63-269992) discloses a method for concentrating milk ganglioside. In the method, a proteolytic enzyme is allowed to act and the resulting proteolytic solution is subjected to ultrafiltration membrane treatment. However, this method has problems that the operation is complicated, there are many impurities, bitterness is generated by the generated peptide, and the taste is bad. Therefore, a composition with a high ganglioside content is used as a milk substitute, as a food material such as a functional food, and as a raw material for pharmaceuticals, in a simple process, and on an industrial scale that can be produced while suppressing the generation of impurities to a low level. The development of manufacturing methods has been strongly desired.
【０００４】[0004]
【発明が解決しようとする課題】本発明は、近年このよ
うに有用性が認められるようになったガングリオシド
を、乳質原料から単純な工程で分離し、夾雑物含量がす
くなく、ガングリオシド含有量の高い組成物を得る方法
を提供することを課題とする。DISCLOSURE OF THE INVENTION The present invention separates gangliosides, which have recently been found to be useful in this way, from a milk material by a simple process, has a low content of contaminants, and a high ganglioside content. It is an object to provide a method of obtaining a composition.
【０００５】[0005]
【課題を解決するための手段】本発明は、ガングリオシ
ドを含有する乳質原料をポアサイズ 1.0μm 以下の精密
濾過膜または分画分子量100,000Da 以上の限外濾過膜で
処理し濃縮してガングリオシド含有量を高めた組成物の
製造方法である。Means for Solving the Problems The present invention is to treat a milk raw material containing a ganglioside with a microfiltration membrane having a pore size of 1.0 μm or less or an ultrafiltration membrane having a cut-off molecular weight of 100,000 Da or more to concentrate the ganglioside content. An improved method of making a composition.
【０００６】さらに、ガングリオシドを含有する乳質原
料をホモジナイズして脂肪球皮膜物質を糖たんぱくまた
は糖脂質から乳清たんぱく質またはカゼインに置換した
後、ポアサイズが 0.1μm 以上で 0.5μm 以下の精密濾
過膜で処理して得られる透過液を、ポアサイズ 0.1μm
未満の精密濾過膜または分画分子量 100,000Da以上の限
外濾過膜で処理して濃縮することでガングリオシド含有
量を高めた組成物の製造方法である。[0006] Furthermore, after homogenizing a milk material containing ganglioside and substituting the fat globule membrane substance from the glycoprotein or glycolipid for whey protein or casein, a microfiltration membrane having a pore size of 0.1 μm or more and 0.5 μm or less is used. The permeate obtained by the treatment has a pore size of 0.1 μm.
A method for producing a composition having an increased ganglioside content by treating with a microfiltration membrane having a molecular weight of less than 100,000 or an ultrafiltration membrane having a molecular weight cutoff of 100,000 Da or more and concentrating.
【０００７】本発明で出発原料として用いる乳質原料
は、ガングリオシドを含有することが知られていれば、
どのような乳質原料でも用いることができる。しかし、
牛乳、山羊乳、羊乳等の乳類からチーズ又はカゼインを
製造する際に副生するホエーを、少量残存しているカー
ドのみをクラリファイヤーで除去して、脂肪を含んだま
まになっているホエーを用いると脂肪球皮膜の含量が多
く、ガングリオシド含量が高いので好ましい。さらに、
このホエーを限外濾過膜を用いて濃縮した乳清たんぱく
質濃縮物、いわゆるＷＰＣを用いることもできる。ま
た、これらホエーおよび乳清たんぱく質濃縮物を噴霧乾
燥して得られた粉体を水に溶解した還元ホエーを用いる
こともできる。The dairy raw material used as a starting material in the present invention is known to contain ganglioside,
Any dairy material can be used. But,
Whey, which is a by-product of cheese, casein production from milk such as milk, goat milk, and sheep milk, is removed by a clarifier to remove only a small amount of curd that remains in the whey. Whey is preferable because it has a large fat globule membrane content and a high ganglioside content. further,
A whey protein concentrate obtained by concentrating this whey using an ultrafiltration membrane, so-called WPC, can also be used. It is also possible to use reduced whey in which powder obtained by spray-drying these whey and whey protein concentrate is dissolved in water.
【０００８】またさらには、牛乳、山羊乳、羊乳等の乳
類およびホエークリームからバターを製造する際に副生
するバターミルクまたはこのバターミルクを噴霧乾燥し
て得たバターミルク粉を水に溶解した還元バターミルク
を用いることもできる。[0008] Furthermore, butter milk produced as a byproduct in the production of butter from milk such as milk, goat milk, and sheep milk and whey cream, or buttermilk powder obtained by spray-drying this buttermilk is added to water. It is also possible to use dissolved reduced buttermilk.
【０００９】上述した乳質原料をポアサイズ 1.0μm 以
下、好ましくは 0.2μm 以下の精密濾過膜または分画分
子量100,000Da 以上、好ましくは500,000Da 以上の限外
濾過膜で処理し、たんぱく質、乳糖、ミネラルを除去す
ることで、ガングリオシドを濃縮することができる。な
お、精密濾過膜の下限値及び限外濾過膜に上限値を設定
していないのは、それぞれの分画特性を精密濾過膜では
ポアサイズ、限外濾過膜では分画分子量で評価している
ためである。すなわち、ポアサイズの小さい精密濾過膜
と分画分子量の大きい限外濾過の境界が明確に定義され
ていないためである。The above-mentioned milk material is treated with a microfiltration membrane having a pore size of 1.0 μm or less, preferably 0.2 μm or less or an ultrafiltration membrane having a molecular weight cutoff of 100,000 Da or more, preferably 500,000 Da or more to remove proteins, lactose and minerals. By removing it, the ganglioside can be concentrated. In addition, the lower limit of the microfiltration membrane and the upper limit of the ultrafiltration membrane are not set because each fractionation property is evaluated by the pore size in the microfiltration membrane and the molecular weight cut-off in the ultrafiltration membrane. Is. That is, the boundary between the microfiltration membrane having a small pore size and the ultrafiltration having a large molecular weight cutoff is not clearly defined.
【００１０】精密濾過膜および限外濾過膜の膜材質は、
高分子材質でも無機材質でもよいが、好ましくはシャー
プな分画性を有している無機材質を用いた膜を使用する
のが望ましい。無機材質の膜としては、アルミナ膜、ジ
ルコニア膜、チタン膜等を例示することができる。The membrane material of the microfiltration membrane and the ultrafiltration membrane is
Although it may be a polymer material or an inorganic material, it is preferable to use a membrane made of an inorganic material having a sharp fractionation property. Examples of the inorganic material film include an alumina film, a zirconia film, and a titanium film.
【００１１】分画分子量100,000Da 未満の限外濾過膜で
は、血清アルブミン、免疫グロブリン等の高分子量の蛋
白質が除去されないため、ガングリオシドを効率的に濃
縮することができない。一方、ポアサイズ 1.0μm より
大きい精密濾過膜では、粒子径の小さい脂肪が透過して
除去されるために、脂肪球皮膜物質として存在するガン
グリオシドの回収効率が低下する。このようにして得ら
れた濃縮液を乾燥して、ガングリオシド含有量の高い粉
末を得る。この粉末中のガングリオシド含有量は、乳質
原料および濃縮倍率により異なるが、 0.1〜2.0 ％であ
った。また、蛋白質50〜80％、糖質５〜20％、灰分１〜
５％で、脂肪含有量は10〜50％と高い値であった。An ultrafiltration membrane having a molecular weight cut-off of less than 100,000 Da cannot remove high molecular weight proteins such as serum albumin and immunoglobulins, so that ganglioside cannot be efficiently concentrated. On the other hand, with a microfiltration membrane having a pore size of more than 1.0 μm, fat with a small particle size is permeated and removed, and thus the recovery efficiency of ganglioside existing as a fat globule membrane substance is reduced. The concentrated solution thus obtained is dried to obtain a powder having a high ganglioside content. The ganglioside content in this powder was 0.1 to 2.0%, although it varied depending on the milk material and the concentration ratio. Also, protein 50-80%, sugar 5-20%, ash 1-
At 5%, the fat content was as high as 10-50%.
【００１２】また、脂肪含有量を低くし、ガングリオシ
ドの含有量を高くした組成物を得る方法としては、乳質
原料あるいは上述した精密濾過膜または限外濾過膜処理
をほどこした脂肪を含むガングリオシド濃縮液を100kg/
cm2 以上でホモジナイズすることによって得ることがで
きる。これはホモジナイズすることによって脂肪球の皮
膜物質である糖たんぱく質、糖脂質が脂肪球から解離し
て水溶性画分に移行し、脂肪球は乳質原料中に同時に含
んでいる乳清たんぱく質またはカゼインと会合し、糖た
んぱく質または糖脂質が乳清たんぱく質またはカゼイン
で置換されて脂肪球皮膜が形成される。また、このさ
い、ホモゲナイズを約50℃前後に加温して行うと前記解
離及び会合を効率的に行うことができる。このようなホ
モゲナイズ処理した乳質原料をポアサイズ0.1μm 以上
で 0.5μm 以下の精密濾過膜で処理して脂肪を濃縮除去
する。得られたガングリオシドを含有する透過液をポア
サイズ 0.1μm 未満の精密濾過膜または分画分子量100,
000Da 以上の限外濾過膜で処理し、たんぱく質、乳糖、
ミネラルを除去することでガングリオシドを濃縮するこ
とができる。このようにして得られた濃縮液を乾燥し
て、ガングリオシド含有量の高い粉末を得る。この粉末
中のガングリオシド含有量は、乳質原料および濃縮倍率
により異なるが、0.1 〜1.5 ％であった。一方、蛋白質
70〜95％、糖質１〜５％、灰分 0.1〜２％で、脂肪含有
量は１〜10％であった。Further, as a method for obtaining a composition having a low fat content and a high ganglioside content, a ganglioside concentrated liquid containing a milk material or a fat subjected to the above microfiltration membrane or ultrafiltration membrane treatment 100 kg /
It can be obtained by homogenizing at cm 2 or more. When homogenized, glycoproteins and glycolipids, which are the film substances of fat globules, dissociate from fat globules and move to the water-soluble fraction, and fat globules are combined with whey protein or casein simultaneously contained in the milk material. Upon association, the glycoprotein or glycolipid is replaced by whey protein or casein to form a fat globule membrane. Further, at this time, if the homogenization is performed by heating at about 50 ° C., the dissociation and association can be efficiently performed. The homogenized milk material is treated with a microfiltration membrane having a pore size of 0.1 μm or more and 0.5 μm or less to concentrate and remove fat. The permeate containing the obtained ganglioside was passed through a microfiltration membrane with a pore size of less than 0.1 μm or a molecular weight cutoff of 100,
Treated with an ultrafiltration membrane of 000 Da or more, protein, lactose,
Gangliosides can be concentrated by removing minerals. The concentrated solution thus obtained is dried to obtain a powder having a high ganglioside content. The ganglioside content in this powder was 0.1 to 1.5%, although it varied depending on the milk material and the concentration ratio. On the other hand, protein
70-95%, sugars 1-5%, ash content 0.1-2%, fat content 1-10%.
【００１３】[0013]
【発明の効果】本発明によれば、乳質原料からガングリ
オシドを高濃度に含有する乳質を工業的規模で安価に、
且つ簡便に効率よく製造することができる。このように
して得られた乳質は、食品素材や医薬品原料として利用
することができ、極めて有用である。According to the present invention, a milk material containing a high concentration of ganglioside from a milk material is manufactured on an industrial scale at a low cost.
In addition, it can be simply and efficiently manufactured. The milk thus obtained can be used as a food material or a raw material for pharmaceuticals and is extremely useful.
【００１４】[0014]
【実施例】以下、実施例に基づき本発明を具体的に説明
する。 実施例１ チェダーチーズホエー100kg をクラリファイアーで残存
するカードを除去し、10℃に冷却してポアサイズ 0.2μ
m の精密濾過膜(TECH-SEP CARBOSEP M20) を用いて10倍
の濃縮と２倍のダイアフィルトレーションにて、濃縮液
10kgを得た。この濃縮液を噴霧乾燥して得られた粉体
は、ガングリオシド0.4 ％、脂肪30％、蛋白質60％、糖
質５％、灰分２％を含んでいた。EXAMPLES The present invention will be specifically described below based on examples. Example 1 100 kg of cheddar cheese whey was removed from the remaining curd with a clarifier, cooled to 10 ° C., and the pore size was 0.2 μm.
Concentrate with 10 times concentration and 2 times diafiltration using m microfiltration membrane (TECH-SEP CARBOSEP M20)
I got 10kg. The powder obtained by spray drying this concentrated solution contained 0.4% ganglioside, 30% fat, 60% protein, 5% sugar, and 2% ash.
【００１５】実施例２ 乳清たんぱく濃縮物（粉体）を水で５％に溶解した溶液
100kg を50℃に加温してポアサイズ 0.5μm の精密濾過
膜（日本ガイシCEFILT-MF)を用いて５倍の濃縮と１倍の
ダイアフィルトレーションにて、濃縮液20kgを得た。こ
の濃縮液を噴霧乾燥して得られた粉体は、ガングリオシ
ド 1.8％、脂肪15％、蛋白質71％、糖質８％、灰分２％
を含んでいた。Example 2 A solution of whey protein concentrate (powder) dissolved in water to 5%
20 kg of a concentrated solution was obtained by heating 100 kg to 50 ° C. and performing 5-fold concentration and 1-fold diafiltration using a microfiltration membrane (NGK CEFILT-MF) having a pore size of 0.5 μm. The powder obtained by spray-drying this concentrated liquid is ganglioside 1.8%, fat 15%, protein 71%, sugar 8%, ash 2%
Was included.
【００１６】実施例３ バターミルク100kg を10℃に冷却して分画分子量500,00
0Da の限外濾過膜(Romicon PM500) を用いて５倍の濃縮
と１倍のダイアフィルトレーションにて、濃縮液20kgを
得た。この濃縮液を噴霧乾燥して得られた粉体は、ガン
グリオシド0.2％、脂肪15％、蛋白質64％、糖質16％、
灰分２％を含んでいた。Example 3 100 kg of buttermilk was cooled to 10 ° C. and the molecular weight cutoff was 500,00.
20 kg of concentrated liquid was obtained by 5 times concentration and 1 time diafiltration using a 0 Da ultrafiltration membrane (Romicon PM500). The powder obtained by spray-drying this concentrated liquid is 0.2% ganglioside, 15% fat, 64% protein, 16% sugar,
It contained 2% ash.
【００１７】実施例４ 乳清たんぱく濃縮物100kg を50℃に加温してホモジナイ
ズ後、ポアサイズ0.1μm の精密濾過膜 (東陶機器 TOTO
セラミック膜) を用いて５倍の濃縮と１倍のダイアフ
ィルトレーションにて、透過液100kg を得た。この透過
液を200,000Daの限外濾過膜 (東陶機器 TOTO セラミッ
ク膜) を用いて５倍の濃縮と１倍のダィアフィルトレー
ションにて、濃縮液２０kgを得た。この濃縮液を噴霧乾
燥して得られた粉体は、ガングリオシド1.5 ％、脂肪３
％、蛋白質91.5％、糖質２％、灰分 0.5％を含んでい
た。Example 4 100 kg of whey protein concentrate was heated to 50 ° C. and homogenized, and then a microfiltration membrane having a pore size of 0.1 μm (Totoki TOTO
100 kg of permeated liquid was obtained by 5 times concentration and 1 time diafiltration using a ceramic membrane). This permeate was concentrated 5 times using a 200,000 Da ultrafiltration membrane (Toto Kikai TOTO Ceramic Membrane) and 1 time diafiltration to obtain 20 kg of a concentrated solution. The powder obtained by spray-drying this concentrated liquid was ganglioside 1.5%, fat 3
%, Protein 91.5%, sugar 2%, and ash 0.5%.
【００１８】実施例５ 実施例１で得られた濃縮液10kgを50℃に加温してホモジ
ナイズ後、ポアサイズ0.45μm の精密濾過膜(DDS GRMO.
45PP) を用いて５倍の濃縮と２倍のダイアフィルトレー
ションにて、透過液12kgを得た。この透過液を200,000D
a の限外濾過膜(TECH-SEP IRIS 3026)を用いて６倍の濃
縮と１倍のダイアフィルトレーションにて、濃縮液２kg
を得た。この濃縮液を噴霧乾燥して得られた粉体は、ガ
ングリオシド1.2 ％、脂肪８％、蛋白質86％、糖質 1.5
％、灰分 0.5％を含んでいた。Example 5 10 kg of the concentrated solution obtained in Example 1 was heated to 50 ° C. and homogenized, and then a microfiltration membrane (DDS GRMO.
12 kg of permeate was obtained by 5 times concentration and 2 times diafiltration using 45PP). 200,000D of this permeate
Concentrated liquid 2kg with 6 times concentration and 1 time diafiltration using a ultrafiltration membrane (TECH-SEP IRIS 3026).
Got The powder obtained by spray-drying this concentrated liquid was ganglioside 1.2%, fat 8%, protein 86%, sugar 1.5%.
% And ash content 0.5%.
【００１９】実施例６ 実施例３で得られた濃縮液20kgを50℃に加温してホモジ
ナイズ後、ポアサイズ0.2μm の精密濾過膜(SCT MEMBRA
LOX) を用いて10倍の濃縮と２倍のダイアフィルトレー
ションにて、透過液12kgを得た。この透過液を550,000D
a の限外濾過膜(東陶機器 TOTO セラミック膜) を用い
て６倍の濃縮と１倍のダイアフィルトレーションにて、
濃縮液２kgを得た。この濃縮液を噴霧乾燥して得られた
粉体は、ガングリオシド1.0 ％、脂肪10％、蛋白質85
％、糖質 1.5％、灰分0.5 ％を含んでいた。Example 6 20 kg of the concentrated solution obtained in Example 3 was heated to 50 ° C. and homogenized, and then a microfiltration membrane (SCT MEMBRA) having a pore size of 0.2 μm was used.
12 kg of permeate was obtained by 10-fold concentration and 2-fold diafiltration using LOX). This permeate is 550,000D
Using a ultrafiltration membrane (a) (Totoki Kikai TOTO Ceramic Membrane) with 6 times concentration and 1 time diafiltration,
2 kg of concentrated liquid was obtained. The powder obtained by spray-drying this concentrate is 1.0% ganglioside, 10% fat, 85% protein.
%, Sugar 1.5%, and ash 0.5%.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 柳平 修一 埼玉県鶴ケ島市富士見３−15−103 (72)発明者 小林 智子 埼玉県大宮市今羽町47−７ ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Inventor Shuichi Yanagihira 3-15-103 Fujimi, Tsurugashima City, Saitama Prefecture (72) Inventor Tomoko Kobayashi 47-7 Imahacho, Omiya City, Saitama Prefecture
Claims (4)
アサイズ 1.0μm 以下の精密濾過膜または分画分子量10
0,000Da 以上の限外濾過膜で処理して濃縮することを特
徴とするガングリオシド含有量の高い組成物の製造方
法。1. A dairy raw material containing a ganglioside is used as a microfiltration membrane having a pore size of 1.0 μm or less or a molecular weight cutoff of 10
A method for producing a composition having a high ganglioside content, which comprises treating with an ultrafiltration membrane having a density of at least 000 Da and then concentrating.
モゲナイズ後、ポアサイズが 0.1μm 以上で 0.5μm 以
下の精密濾過膜で処理して得られる透過液を、ポアサイ
ズ 0.1μm 未満の精密濾過膜または分画分子量100,000D
a 以上の限外濾過膜で処理して濃縮することを特徴とす
るガングリオシド含有量の高い組成物の製造方法。2. A permeated liquid obtained by homogenizing a dairy raw material containing ganglioside and then treating it with a microfiltration membrane having a pore size of 0.1 μm or more and 0.5 μm or less to obtain a microfiltration membrane having a pore size of less than 0.1 μm or a molecular weight cutoff. 100,000D
a A method for producing a composition having a high ganglioside content, which comprises treating with an ultrafiltration membrane as described above and concentrating.
アサイズ 1.0μm 以下の精密濾過膜または分画分子量10
0,000Da 以上の限外濾過膜で処理して濃縮し、この濃縮
液を乳質原料として用いる請求項２記載の方法。3. A dairy raw material containing a ganglioside is used as a microfiltration membrane having a pore size of 1.0 μm or less or a molecular weight cutoff of 10
The method according to claim 2, wherein the concentrated liquid is treated with an ultrafiltration membrane having a density of not less than 10,000 Da and concentrated, and the concentrated liquid is used as a milk material.
乳質ホエー、乳清たんぱく濃縮物またはバターミルクで
ある請求項１乃至３いずれか記載の方法。4. A dairy raw material containing ganglioside,
4. The method according to any one of claims 1 to 3, which is milk whey, whey protein concentrate or buttermilk.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10070892A JP3176698B2 (en) | 1992-03-26 | 1992-03-26 | Method for producing ganglioside-containing composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10070892A JP3176698B2 (en) | 1992-03-26 | 1992-03-26 | Method for producing ganglioside-containing composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH05269353A true JPH05269353A (en) | 1993-10-19 |
| JP3176698B2 JP3176698B2 (en) | 2001-06-18 |
Family
ID=14281186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10070892A Expired - Lifetime JP3176698B2 (en) | 1992-03-26 | 1992-03-26 | Method for producing ganglioside-containing composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3176698B2 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996005844A1 (en) * | 1994-08-24 | 1996-02-29 | Milupa Gmbh & Co. Kg | Allergy-protective formula food with gangliosides |
| WO2004080475A1 (en) * | 2003-03-14 | 2004-09-23 | Meiji Dairies Corporation | Composition against infection with rotavirus and process for producing the same |
| JP2006158340A (en) * | 2004-12-09 | 2006-06-22 | Snow Brand Milk Prod Co Ltd | Method for producing material highly containing compound lipid and material highly containing compound lipid |
| JP2007055921A (en) * | 2005-08-23 | 2007-03-08 | Nagasaki Univ | Binder to vacuolation toxin of helicobacter pylori |
| US9055752B2 (en) | 2008-11-06 | 2015-06-16 | Intercontinental Great Brands Llc | Shelf-stable concentrated dairy liquids and methods of forming thereof |
| US11490629B2 (en) | 2010-09-08 | 2022-11-08 | Koninklijke Douwe Egberts B.V. | High solids concentrated dairy liquids |
-
1992
- 1992-03-26 JP JP10070892A patent/JP3176698B2/en not_active Expired - Lifetime
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996005844A1 (en) * | 1994-08-24 | 1996-02-29 | Milupa Gmbh & Co. Kg | Allergy-protective formula food with gangliosides |
| WO2004080475A1 (en) * | 2003-03-14 | 2004-09-23 | Meiji Dairies Corporation | Composition against infection with rotavirus and process for producing the same |
| JPWO2004080475A1 (en) * | 2003-03-14 | 2006-06-08 | 明治乳業株式会社 | Anti-rotavirus infectious composition and method for producing the same |
| AU2004218981B2 (en) * | 2003-03-14 | 2010-09-16 | Meiji Dairies Corporation | Compositions against rotavirus infection and processes for producing the same |
| JP2012012391A (en) * | 2003-03-14 | 2012-01-19 | Meiji Co Ltd | Composition against infection with rotavirus and process for producing the same |
| US8211476B2 (en) | 2003-03-14 | 2012-07-03 | Meiji Co., Ltd. | Compositions against rotavirus infection and processes for producing the same |
| US8440233B2 (en) | 2003-03-14 | 2013-05-14 | Meiji Co., Ltd | Compositions against rotavirus infection and processes for producing the same |
| JP2006158340A (en) * | 2004-12-09 | 2006-06-22 | Snow Brand Milk Prod Co Ltd | Method for producing material highly containing compound lipid and material highly containing compound lipid |
| JP2007055921A (en) * | 2005-08-23 | 2007-03-08 | Nagasaki Univ | Binder to vacuolation toxin of helicobacter pylori |
| US9055752B2 (en) | 2008-11-06 | 2015-06-16 | Intercontinental Great Brands Llc | Shelf-stable concentrated dairy liquids and methods of forming thereof |
| US11490629B2 (en) | 2010-09-08 | 2022-11-08 | Koninklijke Douwe Egberts B.V. | High solids concentrated dairy liquids |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3176698B2 (en) | 2001-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2622789B2 (en) | Method for producing a fraction having a high content of α-lactalbumin from whey and breast milk substitute or nutritional composition containing said fraction | |
| NO894693D0 (en) | MIXTURE PROTEIN MIXTURE, PROCEDURE FOR THE PREPARATION AND APPLICATION OF THEREOF. | |
| JPH04198198A (en) | Production of kappa-casein glycomacropeptide | |
| US11116233B2 (en) | Process for producing infant formula products and acidic dairy products from milk | |
| JP4250254B2 (en) | Whey protein concentrate and method for producing the same | |
| WO2001003515A9 (en) | Method of obtaining protein isolates and concentrates from colostrum | |
| US20030026845A1 (en) | Process for preparing protein isolate from milk, whey, colostrum, and the like | |
| JP3035833B2 (en) | Method for producing sialic acids-containing composition | |
| JP2961625B2 (en) | Method for producing a composition having a high content of α-lactalbumin | |
| JP3929085B2 (en) | Method for producing ganglioside-rich composition | |
| JPH05269353A (en) | Production of high-ganglioside composition | |
| JPH01168693A (en) | Production of composition containing sialic acids | |
| JP7372232B2 (en) | Method for producing a composition containing κ-casein glycomacropeptide | |
| JP3411965B2 (en) | Method for producing polyamine-containing composition | |
| JP2000234001A (en) | Preparation of high content ganglioside composition | |
| JP3044487B2 (en) | Method for producing a composition containing sialic acids and having a high α-lactalbumin content | |
| JP2900953B2 (en) | Process for producing a milk fraction having a high content of α-lactalbumin and a product containing the fraction | |
| JPH05271295A (en) | Production of composition with high content of kappa-caseinglycomacropeptide | |
| AU2006233196B2 (en) | Enriched milk products | |
| Mulvihill et al. | Production of whey-protein-enriched products | |
| RU2793406C2 (en) | Method of producing products for baby food and milk products | |
| JPS6054637A (en) | Preparation of composition containing nitrogen component in nonprotein state | |
| RU2793288C2 (en) | Method of producing baby food and fermented milk products from milk | |
| JP3029684B2 (en) | Production method of milk fraction having high content of α-lactalbumin by ultrafiltration method | |
| CN117281175A (en) | Whey cheese and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090406 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090406 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100406 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110406 Year of fee payment: 10 |
|
| EXPY | Cancellation because of completion of term |